{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T02:08:03Z","timestamp":1785550083829,"version":"3.56.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-033558"],"award-info":[{"award-number":["INV-033558"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009054","name":"U.S. President\u2019s Emergency Plan for AIDS Relief","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U41HG006941"],"award-info":[{"award-number":["U41HG006941"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CSA2020NoE-3104 TESAIII CSA2020NoE"],"award-info":[{"award-number":["CSA2020NoE-3104 TESAIII CSA2020NoE"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U01 GH000447"],"award-info":[{"award-number":["U01 GH000447"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["U2G GH001911"],"award-info":[{"award-number":["U2G GH001911"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011858","name":"African Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"publisher","award":["5D43TW009610"],"award-info":[{"award-number":["5D43TW009610"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.jgar.2022.08.008","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T11:58:10Z","timestamp":1660391890000},"page":"128-134","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Doravirine-associated resistance mutations in antiretroviral therapy na\u00efve and experienced adults with HIV-1 subtype C infection in Botswana"],"prefix":"10.1016","volume":"31","author":[{"given":"Ontlametse T.","family":"Bareng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sekgabo","family":"Seselamarumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaelo K.","family":"Seatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wonderful T.","family":"Choga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3915-8353","authenticated-orcid":false,"given":"Blessing","family":"Bakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas","family":"Maruapula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2433-2416","authenticated-orcid":false,"given":"Nametso","family":"Kelentse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5333-4010","authenticated-orcid":false,"given":"Natasha O.","family":"Moraka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baitshepi","family":"Mokaleng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick T.","family":"Mokgethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsotlhe R.","family":"Ditlhako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-2376","authenticated-orcid":false,"given":"Molly","family":"Pretorius-Holme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mpaphi B.","family":"Mbulawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refeletswe","family":"Lebelonyane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebi Celestin","family":"Bile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tendani","family":"Gaolathe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4832-6275","authenticated-orcid":false,"given":"Roger","family":"Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Makhema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5384-9716","authenticated-orcid":false,"given":"Shahin","family":"Lockman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Essex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Novitsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0147-1819","authenticated-orcid":false,"given":"Sununguko W.","family":"Mpoloka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3821-4592","authenticated-orcid":false,"given":"Sikhulile","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simani","family":"Gaseitsiwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2022.08.008_bib0001","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s10461-014-0927-4","article-title":"Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART)","volume":"19","author":"Viswanathan","year":"2015","journal-title":"AIDS Behav"},{"key":"10.1016\/j.jgar.2022.08.008_bib0002","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/INF.0000000000002347","article-title":"Association of antiretroviral drug regimen with viral suppression in HIV-positive children on antiretroviral therapy in Eswatini","volume":"38","author":"Chouraya","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2022.08.008_bib0003","doi-asserted-by":"crossref","unstructured":"Gulick RM. New HIV drugs: 2018 and beyond. https:\/\/doi.org\/10.1097\/coh.0000000000000478.","DOI":"10.1097\/COH.0000000000000478"},{"key":"10.1016\/j.jgar.2022.08.008_bib0004","unstructured":"Clayden P. Dolutegravir preconception signal: time is up for shoddy surveillance. https:\/\/i-base.info\/htb\/34459. [Accessed 08 June 2021]."},{"issue":"Suppl. 2","key":"10.1016\/j.jgar.2022.08.008_bib0005","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1093\/infdis\/jit121","article-title":"The impact of HIV drug resistance on the selection of first- and second-line ART in resource-limited settings","volume":"207","author":"Bertagnolio","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2022.08.008_bib0006","unstructured":"World Health Organization. HIV drug resistance report 2012. https:\/\/www.who.int\/hiv\/pub\/drugresistance\/report2012\/en\/; 2012. [Accessed 17 June 2021]."},{"key":"10.1016\/j.jgar.2022.08.008_bib0007","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0000000000000509","article-title":"Population-based surveillance of HIV drug resistance emerging on treatment and associated factors at sentinel antiretroviral therapy sites in Namibia. Journal of acquired immune deficiency syndromes (1999)","volume":"68","author":"Hong","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jgar.2022.08.008_bib0008","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12981-019-0220-8","article-title":"High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up","volume":"16","author":"Rutstein","year":"2019","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.jgar.2022.08.008_bib0009","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkv500","article-title":"Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance","volume":"71","author":"Rowley","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0010","unstructured":"World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. https:\/\/www.who.int\/publications\/i\/item\/9789241550062; 2017 [accessed 10 March 2020]."},{"key":"10.1016\/j.jgar.2022.08.008_bib0011","doi-asserted-by":"crossref","first-page":"e25227","DOI":"10.1002\/jia2.25227","article-title":"Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort","volume":"22","author":"Mondi","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2022.08.008_bib0012","unstructured":"World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance. https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/273632\/WHO-CDS-HIV-18.18-eng.pdf; 2018. [Accessed 18 July 2021.]"},{"key":"10.1016\/j.jgar.2022.08.008_bib0013","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1097\/QAD.0000000000001920","article-title":"Four-class drug-resistant HIV-1 subtype C in a treatment experienced individual on dolutegravir-based antiretroviral therapy in Botswana","volume":"32","author":"Seatla","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.08.008_bib0014","first-page":"13","article-title":"HIV-1 subtype C drug resistance mutations in heavily treated patients failing integrase strand transfer inhibitor-based regimens in Botswana","author":"Seatla","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jgar.2022.08.008_bib0015","article-title":"A heavily treated HIV-1 infected patient with multiclass drug resistance: a case report and review of management challenges in settings with a limited formulary","volume":"7","author":"Rugemalila","year":"2021","journal-title":"Med Case Rep"},{"key":"10.1016\/j.jgar.2022.08.008_bib0016","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1128\/AAC.02650-15","article-title":"Doravirine suppresses common nonnucleoside reverse transcriptase inhibitor-associated mutants at clinically relevant concentrations","volume":"60","author":"Feng","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0017","doi-asserted-by":"crossref","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","article-title":"Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial","volume":"5","author":"Molina","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jgar.2022.08.008_bib0018","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/cid\/ciy540","article-title":"Doravirine\/lamivudine\/tenofovir disoproxil fumarate is non-inferior to efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: week 48 results of the DRIVE-AHEAD Trial","volume":"68","author":"Orkin","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2022.08.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01216-21","article-title":"Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates","volume":"65","author":"Asante-Appiah","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0020","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1812281","article-title":"Universal testing, expanded treatment, and incidence of HIV infection in Botswana","volume":"381","author":"Makhema","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2022.08.008_bib0021","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0000000000002166","article-title":"Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana","volume":"33","author":"Moyo","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.08.008_bib0022","unstructured":"Ministry of Health. Botswana integrated HIV clinical care guidelines 2016. https:\/\/www.childrenandaids.org\/Botswana_Integrated-HIV-Clinical-Care-Guidelines_2016. [Accessed 23 July 2021]."},{"key":"10.1016\/j.jgar.2022.08.008_bib0023","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1128\/JCM.00756-15","article-title":"Long-range HIV genotyping using viral RNA and proviral DNA for analysis of HIV drug resistance and HIV clustering","volume":"53","author":"Novitsky","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jgar.2022.08.008_bib0024","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.meegid.2013.04.032","article-title":"Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools","volume":"19","author":"Pineda-Pe\u00f1a","year":"2013","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jgar.2022.08.008_bib0025","doi-asserted-by":"crossref","first-page":"e144","DOI":"10.1093\/nar\/gku739","article-title":"COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification","volume":"42","author":"Struck","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jgar.2022.08.008_bib0026","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/bioinformatics\/16.4.400","article-title":"Detecting hypermutations in viral sequences with an emphasis on G \u2013>A hypermutation","volume":"16","author":"Rose","year":"2000","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jgar.2022.08.008_bib0027","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/13596535211043044","article-title":"Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients","volume":"26","author":"Scheibe","year":"2021","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jgar.2022.08.008_bib0028","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/jac\/dkac016","article-title":"Prevalence of doravirine cross-resistance in HIV-infected adults who failed first-line ART in China, 2014\u201318","volume":"77","author":"Sun","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0029","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/jac\/dkab385","article-title":"Deep sequencing of HIV-1 reveals extensive subtype variation and drug resistance after failure of first-line antiretroviral regimens in Nigeria","volume":"77","author":"El Bouzidi","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0030","article-title":"Rare occurrence of doravirine resistance-associated mutations in HIV-1-infected treatment-naive patients","volume":"74","author":"Souli\u00e9","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0031","doi-asserted-by":"crossref","first-page":"e25706","DOI":"10.1002\/jia2.25706","article-title":"Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa","volume":"24","author":"Steegen","year":"2021","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jgar.2022.08.008_bib0032","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/jac\/dkz553","article-title":"Prevalence of doravirine-associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy","volume":"75","author":"Soulie","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0033","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ijantimicag.2019.02.007","article-title":"Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors","volume":"53","author":"Sterrantino","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2022.08.008_bib0034","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/jac\/dkaa401","article-title":"In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations","volume":"76","author":"Saladini","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2022.08.008_bib0035","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1097\/QAD.0000000000001862","article-title":"Undisclosed antiretroviral drug use in Botswana: implication for national estimates","volume":"32","author":"Moyo","year":"2018","journal-title":"AIDS"},{"key":"10.1016\/j.jgar.2022.08.008_bib0036","doi-asserted-by":"crossref","DOI":"10.1097\/QAI.0000000000002056","article-title":"Switching to doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial","volume":"81","author":"Johnson","year":"2019","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716522001989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:01:43Z","timestamp":1761991303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716522001989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":36,"alternative-id":["S2213716522001989"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2022.08.008","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doravirine-associated resistance mutations in antiretroviral therapy na\u00efve and experienced adults with HIV-1 subtype C infection in Botswana","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2022.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}